Search research articles
Contact Us
Filters
Showing results (261-270 of 270) with videos related to
Page
of 27
Sort By:
You have reached the last page of results.
This site can display upto 270 results.
European Urology
|
April 15, 2017
An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer
Roland Seiler, Htoo Zarni Oo, Davide Tortora, et al.
The Journal of Pathology
|
February 2, 2012
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer
Chunxiao Wu, Alexander W Wyatt, Anna V Lapuk, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 9, 2025
Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study
Yen-Yi Lin, Hamideh Sharifi Noghabi, Stanislav Volik, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 21, 2023
Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study
Palak Patel, Stephanie Harmon, Rachael Iseman, et al.
The Journal of Pathology
|
May 4, 2012
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer
Anna V Lapuk, Chunxiao Wu, Alexander W Wyatt, et al.
Cancer Cell
|
October 14, 2015
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein
Ali Salanti, Thomas M Clausen, Mette Ø Agerbæk, et al.
Nature Communications
|
July 26, 2017
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, et al.
Nature Communications
|
June 6, 2019
Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, et al.
Nature Communications
|
January 19, 2019
ONECUT2 is a driver of neuroendocrine prostate cancer
Haiyang Guo, Xinpei Ci, Musaddeque Ahmed, et al.
EMBO Molecular Medicine
|
January 11, 2022
THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer
Arnaud Blomme, Coralie Peter, Ernest Mui, et al.
Page
of 27
Search research articles
Search
Showing results (261-270 of 270) with videos related to
Sort By:
Page
of 27
You have reached the last page of results.
This site can display upto 270 results.
European Urology
|
April 15, 2017
An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer
Roland Seiler, Htoo Zarni Oo, Davide Tortora, et al.
The Journal of Pathology
|
February 2, 2012
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer
Chunxiao Wu, Alexander W Wyatt, Anna V Lapuk, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 9, 2025
Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study
Yen-Yi Lin, Hamideh Sharifi Noghabi, Stanislav Volik, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 21, 2023
Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study
Palak Patel, Stephanie Harmon, Rachael Iseman, et al.
The Journal of Pathology
|
May 4, 2012
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer
Anna V Lapuk, Chunxiao Wu, Alexander W Wyatt, et al.
Cancer Cell
|
October 14, 2015
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein
Ali Salanti, Thomas M Clausen, Mette Ø Agerbæk, et al.
Nature Communications
|
July 26, 2017
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, et al.
Nature Communications
|
June 6, 2019
Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, et al.
Nature Communications
|
January 19, 2019
ONECUT2 is a driver of neuroendocrine prostate cancer
Haiyang Guo, Xinpei Ci, Musaddeque Ahmed, et al.
EMBO Molecular Medicine
|
January 11, 2022
THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer
Arnaud Blomme, Coralie Peter, Ernest Mui, et al.
Page
of 27